VICARIOUS SURGICAL INC-A (RBOT) Fundamental Analysis & Valuation
NYSE:RBOT • US92561V2088
Current stock price
1.92 USD
-0.12 (-5.88%)
At close:
1.98 USD
+0.06 (+3.13%)
After Hours:
This RBOT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RBOT Profitability Analysis
1.1 Basic Checks
- In the past year RBOT has reported negative net income.
- RBOT had a negative operating cash flow in the past year.
- In the past 5 years RBOT reported 4 times negative net income.
- RBOT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- RBOT's Return On Assets of -182.62% is on the low side compared to the rest of the industry. RBOT is outperformed by 89.67% of its industry peers.
- The Return On Equity of RBOT (-380.42%) is worse than 79.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -182.62% | ||
| ROE | -380.42% | ||
| ROIC | N/A |
ROA(3y)-49.66%
ROA(5y)-48.14%
ROE(3y)-67.76%
ROE(5y)-64.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- RBOT has a Gross Margin of 5.76%. This is amonst the worse of the industry: RBOT underperforms 81.52% of its industry peers.
- The Profit Margin and Operating Margin are not available for RBOT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 5.76% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. RBOT Health Analysis
2.1 Basic Checks
- RBOT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for RBOT has been increased compared to 1 year ago.
- Compared to 5 years ago, RBOT has less shares outstanding
- There is no outstanding debt for RBOT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- RBOT has an Altman-Z score of -15.74. This is a bad value and indicates that RBOT is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of RBOT (-15.74) is worse than 86.96% of its industry peers.
- There is no outstanding debt for RBOT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.74 |
ROIC/WACCN/A
WACC10.05%
2.3 Liquidity
- A Current Ratio of 4.75 indicates that RBOT has no problem at all paying its short term obligations.
- RBOT has a Current ratio of 4.75. This is in the better half of the industry: RBOT outperforms 73.37% of its industry peers.
- A Quick Ratio of 4.75 indicates that RBOT has no problem at all paying its short term obligations.
- RBOT has a Quick ratio of 4.75. This is in the better half of the industry: RBOT outperforms 79.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.75 | ||
| Quick Ratio | 4.75 |
3. RBOT Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 12.05% over the past year.
- The Revenue has grown by 160.31% in the past year. This is a very strong growth!
EPS 1Y (TTM)12.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.86%
Revenue 1Y (TTM)160.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 19.05% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.95%
EPS Next 2Y27.18%
EPS Next 3Y19.05%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. RBOT Valuation Analysis
4.1 Price/Earnings Ratio
- RBOT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RBOT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RBOT's earnings are expected to grow with 19.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.18%
EPS Next 3Y19.05%
5. RBOT Dividend Analysis
5.1 Amount
- RBOT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RBOT Fundamentals: All Metrics, Ratios and Statistics
1.92
-0.12 (-5.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners33.26%
Inst Owner Change27.22%
Ins Owners1.9%
Ins Owner Change-0.01%
Market Cap13.67M
Revenue(TTM)21.69M
Net Income(TTM)-53.59M
Analysts43.33
Price Target5.1 (165.63%)
Short Float %1.44%
Short Ratio0.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.03%
Min EPS beat(2)12.43%
Max EPS beat(2)21.62%
EPS beat(4)3
Avg EPS beat(4)11.32%
Min EPS beat(4)-2.78%
Max EPS beat(4)21.62%
EPS beat(8)5
Avg EPS beat(8)11.53%
EPS beat(12)8
Avg EPS beat(12)11.45%
EPS beat(16)9
Avg EPS beat(16)9.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-44.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.97 | ||
| P/tB | 0.97 | ||
| EV/EBITDA | N/A |
EPS(TTM)-9.05
EYN/A
EPS(NY)-4.15
Fwd EYN/A
FCF(TTM)-6.72
FCFYN/A
OCF(TTM)-6.68
OCFYN/A
SpS3.05
BVpS1.98
TBVpS1.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -182.62% | ||
| ROE | -380.42% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 5.76% | ||
| FCFM | N/A |
ROA(3y)-49.66%
ROA(5y)-48.14%
ROE(3y)-67.76%
ROE(5y)-64.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.75 | ||
| Quick Ratio | 4.75 | ||
| Altman-Z | -15.74 |
F-Score3
WACC10.05%
ROIC/WACCN/A
Cap/Depr(3y)193.53%
Cap/Depr(5y)211.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.86%
EPS Next Y23.95%
EPS Next 2Y27.18%
EPS Next 3Y19.05%
EPS Next 5YN/A
Revenue 1Y (TTM)160.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.85%
EBIT Next 3Y23.49%
EBIT Next 5YN/A
FCF growth 1Y32.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.43%
OCF growth 3YN/A
OCF growth 5YN/A
VICARIOUS SURGICAL INC-A / RBOT Fundamental Analysis FAQ
What is the ChartMill fundamental rating of VICARIOUS SURGICAL INC-A (RBOT) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RBOT.
What is the valuation status of VICARIOUS SURGICAL INC-A (RBOT) stock?
ChartMill assigns a valuation rating of 0 / 10 to VICARIOUS SURGICAL INC-A (RBOT). This can be considered as Overvalued.
Can you provide the profitability details for VICARIOUS SURGICAL INC-A?
VICARIOUS SURGICAL INC-A (RBOT) has a profitability rating of 0 / 10.